(Q34315535)

English

The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

11 references

13 March 2019

17 June 2019

30 June 2019

1 August 2019

27 September 2019

20 November 2019

27 November 2019

13 December 2019

14 November 2020

1 February 2021

28 October 2022

0 references

The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

0 references

0 references

0 references

0 references

rheumatoid arthritis

9 references

13 March 2019

17 June 2019

30 June 2019

1 August 2019

27 September 2019

20 November 2019

27 November 2019

13 December 2019

14 November 2020

tumor necrosis factor

2 references

1 August 2019

1 February 2021

monoclonal antibody

1 reference

27 September 2019

1 reference

20 November 2019

1 reference

27 November 2019

1 reference

13 December 2019

disease-modifying antirheumatic drug

1 reference

14 November 2020

systematic review

1 reference

based on heuristic

inferred from title

Sylwia Bujkiewicz

object named as

Sylwia Bujkiewicz

2

0 references

4

object named as

Alex J Sutton

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

3

object named as

Allan J Wailoo

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

author name string

Suzanne Lloyd

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

David Scott

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

21 June 2010

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1 December 2010

11 references

13 March 2019

17 June 2019

30 June 2019

1 August 2019

27 September 2019

20 November 2019

27 November 2019

13 December 2019

14 November 2020

1 February 2021

28 October 2022

12 references

Europe PubMed Central

PubMed publication ID

1 August 2017

13 March 2019

17 June 2019

30 June 2019

1 August 2019

27 September 2019

20 November 2019

27 November 2019

13 December 2019

14 November 2020

1 February 2021

28 October 2022

49

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

2313-2321

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

copyright license

Creative Commons Attribution-NonCommercial 2.5 Generic

11 references

Europe PubMed Central

13 March 2019

Europe PubMed Central

17 June 2019

Europe PubMed Central

30 June 2019

Europe PubMed Central

1 August 2019

Europe PubMed Central

27 September 2019

Europe PubMed Central

20 November 2019

Europe PubMed Central

27 November 2019

Europe PubMed Central

13 December 2019

Europe PubMed Central

14 November 2020

Europe PubMed Central

1 February 2021

Europe PubMed Central

28 October 2022

on focus list of Wikimedia project

0 references

DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

6 July 2018

Postmarketing surveillance of the safety and effectiveness of etanercept in Japan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

6 July 2018

Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

6 July 2018

Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

6 July 2018

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

6 July 2018

Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

6 July 2018

Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

6 July 2018

Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

6 July 2018

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

6 July 2018

Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

6 July 2018

Meta-analysis of heterogeneously reported trials assessing change from baseline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

6 July 2018

Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

6 July 2018

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

6 July 2018

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

6 July 2018

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

6 July 2018

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

6 July 2018

The costs of rheumatoid arthritis: an international long-term view

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

6 July 2018

The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

6 July 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

28 October 2018

Biologic drugs for rheumatoid arthritis in the medicare program: A cost-effectiveness analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

28 October 2018

Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

28 October 2018

Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2982750

28 October 2018

The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century

1 reference

https://pubmed.ncbi.nlm.nih.gov/20566736

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept

1 reference

https://pubmed.ncbi.nlm.nih.gov/20566736

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept

1 reference

https://pubmed.ncbi.nlm.nih.gov/20566736

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure

1 reference

https://pubmed.ncbi.nlm.nih.gov/20566736

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/20566736

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20566736

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/20566736

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept

1 reference

https://pubmed.ncbi.nlm.nih.gov/20566736

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/20566736

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20566736

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register

1 reference

https://pubmed.ncbi.nlm.nih.gov/20566736

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20566736

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NICE guidelines on anti-tumor necrosis factor therapy for RA

1 reference

https://pubmed.ncbi.nlm.nih.gov/20566736

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20566736

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/RHEUMATOLOGY/KEQ169

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34315535&oldid=2049770976"